S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
This Skill Could Change The Way You Trade! (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
China fines former NBA star Lin over quarantine comments
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
This Skill Could Change The Way You Trade! (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
China fines former NBA star Lin over quarantine comments
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
This Skill Could Change The Way You Trade! (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
China fines former NBA star Lin over quarantine comments
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
This Skill Could Change The Way You Trade! (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
China fines former NBA star Lin over quarantine comments
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
NASDAQ:NVAX

Novavax - NVAX Stock Forecast, Price & News

$16.52
-0.33 (-1.96%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$15.53
$16.55
50-Day Range
$16.30
$25.04
52-Week Range
$15.53
$236.50
Volume
6.18 million shs
Average Volume
5.72 million shs
Market Capitalization
$1.30 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$109.25

Novavax MarketRank™ Forecast

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
561.3% Upside
$109.25 Price Target
Short Interest
Bearish
28.76% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.27
Upright™ Environmental Score
News Sentiment
0.21mentions of Novavax in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($5.19) to ($5.85) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars

Medical Sector

860th out of 1,052 stocks

Biological Products, Except Diagnostic Industry

145th out of 173 stocks

NVAX stock logo

About Novavax (NASDAQ:NVAX) Stock

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Receive NVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter.

NVAX Stock News Headlines

Novavax (NASDAQ:NVAX) Sets New 1-Year Low at $15.86
Novavax Stock: Buy, Sell, or Hold in 2023?
Why Shares of Novavax Are Down Tuesday
Novavax's COVID-19 booster authorized in Canada
Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates
See More Headlines
Receive NVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter.

NVAX Company Calendar

Last Earnings
11/08/2022
Today
12/03/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:NVAX
CUSIP
67000210
Employees
1,541
Year Founded
1987

Price Target and Rating

Average Stock Price Forecast
$109.25
High Stock Price Forecast
$207.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+561.3%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Net Income
$-1,743,750,000.00
Pretax Margin
-70.33%

Debt

Sales & Book Value

Annual Sales
$1.15 billion
Book Value
($7.21) per share

Miscellaneous

Free Float
76,855,000
Market Cap
$1.30 billion
Optionable
Optionable
Beta
1.77

Social Links


Key Executives

  • Mr. Stanley Charles Erck (Age 74)
    Pres, CEO & Director
    Comp: $1.12M
  • Mr. James Patrick Kelly C.F.A. (Age 56)
    Exec. VP, CFO & Treasurer
    Comp: $355.23k
  • Mr. John A. Herrmann IIIMr. John A. Herrmann III (Age 56)
    Exec. VP, Chief Legal Officer & Corp. Sec.
    Comp: $657.8k
  • Mr. John Joseph Trizzino B.S. (Age 62)
    M.B.A., Exec. VP and Chief Bus. & Commercial Officer
    Comp: $636.85k
  • Dr. Gregory M. GlennDr. Gregory M. Glenn (Age 68)
    Pres of R&D
    Comp: $813.44k
  • Mr. Richard P. Crowley (Age 65)
    Exec. VP & COO
  • Dr. Gale E. Smith (Age 72)
    Sr. VP of Discovery & Pre-Clinical Research and Chief Scientist
  • Mr. Biegie Lee
    Sr. VP & Chief Information Officer
  • Mr. Troy Morgan Esq. (Age 51)
    J.D., Sr. VP & Chief Compliance Officer
  • Ms. Erika S. Trahan
    Associate Director of Investor & PR













NVAX Stock - Frequently Asked Questions

Should I buy or sell Novavax stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last twelve months. There are currently 2 sell ratings, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVAX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVAX, but not buy additional shares or sell existing shares.
View NVAX analyst ratings
or view top-rated stocks.

What is Novavax's stock price forecast for 2023?

7 equities research analysts have issued 12 month price targets for Novavax's shares. Their NVAX share price forecasts range from $27.00 to $207.00. On average, they expect the company's stock price to reach $109.25 in the next year. This suggests a possible upside of 561.3% from the stock's current price.
View analysts price targets for NVAX
or view top-rated stocks among Wall Street analysts.

How have NVAX shares performed in 2022?

Novavax's stock was trading at $143.07 at the beginning of the year. Since then, NVAX stock has decreased by 88.5% and is now trading at $16.52.
View the best growth stocks for 2022 here
.

When is Novavax's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our NVAX earnings forecast
.

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) issued its quarterly earnings results on Tuesday, November, 8th. The biopharmaceutical company reported ($2.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.21 by $4.36. The biopharmaceutical company had revenue of $734.58 million for the quarter, compared to analyst estimates of $555.50 million. Novavax had a negative trailing twelve-month return on equity of 572.54% and a negative net margin of 71.59%. The firm's revenue for the quarter was up 310.7% on a year-over-year basis. During the same quarter last year, the business posted ($4.31) EPS.

When did Novavax's stock split?

Novavax shares reverse split before market open on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What guidance has Novavax issued on next quarter's earnings?

Novavax updated its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.00 billion-$2.00 billion, compared to the consensus revenue estimate of $2.04 billion.

What is Stanley C. Erck's approval rating as Novavax's CEO?

46 employees have rated Novavax Chief Executive Officer Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among the company's employees.

What other stocks do shareholders of Novavax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Who are Novavax's major shareholders?

Novavax's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.55%), State Street Corp (4.66%), Credit Suisse AG (1.20%), Renaissance Technologies LLC (1.12%), Coatue Management LLC (0.70%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include David M Mott, Gary C Evans, Gregory M Glenn, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck.
View institutional ownership trends
.

How do I buy shares of Novavax?

Shares of NVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novavax's stock price today?

One share of NVAX stock can currently be purchased for approximately $16.52.

How much money does Novavax make?

Novavax (NASDAQ:NVAX) has a market capitalization of $1.30 billion and generates $1.15 billion in revenue each year. The biopharmaceutical company earns $-1,743,750,000.00 in net income (profit) each year or ($17.30) on an earnings per share basis.

How many employees does Novavax have?

The company employs 1,541 workers across the globe.

How can I contact Novavax?

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The official website for the company is www.novavax.com. The biopharmaceutical company can be reached via phone at (240) 268-2000, via email at ir@novavax.com, or via fax at 240-268-2100.

This page (NASDAQ:NVAX) was last updated on 12/3/2022 by MarketBeat.com Staff